OPK Stock — Opko Health Inc

Opko Health Inc (OPK)

Updated October 16, 2026.

OPK is a Stock. Total return is -66.0% over the past 31 years, 2169.4 points behind SPY at 2103.4%.

Opko Health is a diversified healthcare company operating pharmaceutical and diagnostics businesses across multiple countries. The Pharmaceutical segment develops immunotherapy candidates and other therapeutic products, including growth hormone and metabolic disorder treatments, while the Diagnostics segment provides laboratory testing services under the BioReference brand covering areas such as molecular diagnostics, genetics, and pathology. The company does not currently have an established distribution schedule.

OPK performance versus SPY

Price and return data through 2026-10-16.

Total return is -66.0% over the past 31 years, 2169.4 points behind SPY at 2103.4%. Over the past year its total return — price change plus distributions reinvested — is 2.0%. Its deepest 1-year drawdown was 28.1%.

OPK key facts

Asset type

Stock

Asset class

Equity

Inception date

11/02/1995

Distribution frequency

None

Last close

$1.53 (as of 2026-10-16)

Market cap

$1,141,882,184

Average volume

11974177.0

Beta

1.504

Payout ratio

0.0%

Forward P/E

53.7634

EPS

$-0.09

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

OPK risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 28.1%.

Who may consider OPK — and who may not

It is a weaker fit for investors who need monthly cash flow (OPK does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on OPK

• All tickers starting with O

Tagged: Healthcare.

Frequently asked questions